home / stock / azn / azn articles

AZN Articles, AstraZeneca PLC - From 02/12/24

Stock Information
Company Name: AstraZeneca PLC
Stock Symbol: AZN
Market: NYSE
Website: astrazeneca.com
Menu
AZN AZN Quote AZN Short AZN News AZN Articles AZN Message Board
Get AZN Alerts

News, Short Squeeze, Breakout and More Instantly...
This Analyst Slightly Lowers AstraZeneca Forecast Amid Earnings Concerns, Although Still Bullish on Future Growth Potential | Benzinga

Thursday, AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter 2023 sales of $12.02 billion, up 7% Y/Y (+8% at constant currency), slight...
From Slack To Surveillance: Here's How Companies Monitor Your Communications With AI | Benzinga

In a move reminiscent of George Orwell's surveillance dystopia, companies are now deploying artificial intelligence (AI) to monitor commun...

Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga

Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minera...

AstraZeneca Stock Tumbles After Q4 Performance - Here's Why | Benzinga

AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter 2023 sales of $12.02 billion, up 7% Y/Y (+8% at constant currency), slightly be...
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations | Benzinga

Under the Inflation Reduction Act, Medicare is poised to send initial offers to manufacturers of the first ten drugs chosen for negotiation, challe...

Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares | Benzinga

Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors w...

Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60% | Benzinga

Pharmaceutical companies await the U.S. government’s forthcoming proposal, expected this Thursday, outlining substantial discounts for t...
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment | Benzinga

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell ca...

AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study | Benzinga

AstraZeneca Plc (NASDAQ:AZN) released results from the EMERALD-1 Phase 3 trial of Imfinzi plus TACE concurrently, followed by Imfinz...

Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst | Benzinga

Thursday, Novartis AG (NYSE:NVS) decided to step back from pursuing the Cytokinetics Inc (NASDAQ:CYTK) acquisition, dealin...
Previous 10 Next 10